Background-Prior primary prevention trials of statin therapy that used cholesterol criteria for enrollment have not reported significant decreases in stroke risk. We evaluated whether statin therapy might reduce stroke rates among individuals with low levels of cholesterol but elevated levels of high-sensitivity C-reactive protein.
H yperlipidemia is a well-established risk factor for cardiovascular disease, but its association with coronary heart disease is much stronger than its association with stroke. [1] [2] [3] [4] In prior primary prevention trials that used elevated cholesterol levels as criteria for entry, statin therapy has not demonstrated a reduction in stroke risk. [5] [6] [7] Among patients with established vascular disease or diabetes, however, statin therapy has proven remarkably effective, reducing the risk of stroke by 19% to 48%. 8 -14 
Clinical Perspective on p 150
High-sensitivity C-reactive protein (hsCRP) is an inflammatory biomarker that independently predicts future stroke and improves cardiovascular risk classification, regardless of low-density lipoprotein cholesterol (LDL-C) level. 4, [15] [16] [17] [18] [19] Be-cause of this association and because statin therapy reduces hsCRP levels, we hypothesized that statin therapy would reduce stroke risk in patients with low levels of cholesterol but elevated levels of hsCRP. 20 Furthermore, we hypothesized that the lowest risk of stroke would be observed among those who achieved the lowest levels of LDL-C or hsCRP after initiation of statin therapy.
Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) investigated whether treatment with rosuvastatin 20 mg daily compared with placebo would decrease the rate of first major cardiovascular events. Here, we report the impact of rosuvastatin compared with placebo on incident stroke, a component of the primary end point and a prespecified secondary end point of JUPITER.
Methods

Trial Design
JUPITER was a randomized, double-blind, placebo-controlled multicenter trial conducted at 1315 sites in 26 countries. The study protocol and population are described in detail elsewhere. 21, 22 Briefly, men Ն50 years of age and women Ն60 years of age were eligible for the trial if they did not have a history of cardiovascular disease or diabetes and if they had an LDL-C level Ͻ130 mg/dL (3.4 mmol/L) and an hsCRP Ն2.0 mg/L. Eligible subjects who provided informed consent were randomized to either rosuvastatin 20 mg daily or matching placebo. Lipid levels and hsCRP were measured at randomization and every year thereafter. The 17 802 participants randomized to rosuvastatin or placebo were included in the intention-to-treat analysis of the risk of incident stroke. To address the effect of reductions in hsCRP and LDL-C on stroke risk, we used baseline and 1-year hsCRP and LDL-C concentrations in 15 548 participants (87% of the total) for whom data were available.
End Points
Stroke (fatal or nonfatal) was a predefined end point of the JUPITER trial. An end-points committee blinded to randomized treatment assignment confirmed an incident stroke if there were unequivocal signs of a focal or global neurological deficit with sudden onset and duration Ͼ24 hours. Computed tomography or magnetic resonance imaging scans, as well as other clinical reports, were used to classify stroke types as hemorrhagic, atheroembolic, thromboembolic, or other. Fatal strokes were confirmed if they met the criteria for nonfatal strokes or if the diagnosis was specifically stated in the hospital discharge record, death certificate, or postmortem autopsy examination. Transient ischemic attacks (TIAs) were reported by local site investigators but were not confirmed by the end-points committee.
Statistical Analysis
Analyses of the effect of random allocation to rosuvastatin on incident stroke were performed on an intention-to-treat basis. Cox proportional-hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for the comparison of event rates in the 2 treatment groups. Subgroup analyses were performed according to the presence or absence of major cardiovascular risk factors. To measure the net clinical benefit of rosuvastatin when the combined effects on cerebral and coronary events were considered, we also fitted a proportional-hazards model with the first occurrence of stroke or other major cardiovascular event (nonfatal myocardial infarction, unstable angina, arterial revascularization, or cardiovascular death) as a composite outcome and estimated differences in risk and the number needed to treat for absolute measures of treatment efficacy. 23 For the analysis of achieved LDL-C and incident stroke, on the basis of prior work in JUPITER and in the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat-to-Zocor (A to Z) trials, participants were divided on an a priori basis into groups according to whether the achieved LDL-C levels were Ն70 or Ͻ70 mg/dL at 1 year. 24 -26 Similarly, for the analysis of achieved hsCRP and incident stroke, participants were divided on an a priori basis into groups according to whether the achieved hsCRP levels were Ն2 mg/L or Ͻ2 mg/L at 1 year. Cox proportional-hazards models were used to calculate HRs and 95% CIs for the comparison of event rates in these achieved LDL-C and hsCRP groups compared with placebo. We constructed 3 models: the first adjusted for age; the second adjusted for age, baseline LDL-C, and baseline hsCRP; and the third adjusted for age, baseline LDL-C, baseline high-density lipoprotein cholesterol (HDL-C), baseline hsCRP, blood pressure, sex, body mass index, smoking status, and parental history of premature stroke. We used an integer score variable to test for trend across the placebo group and LDL-C and hsCRP strata. Spearman correlation coefficients were used to evaluate relationships between on-treatment LDL-C and on-treatment hsCRP. Finally, to place these data in context with previous trials of statin therapy in the primary prevention of stroke, we used the R software package to perform a random-effects meta-analysis that included data from JUPITER, the West of Scotland Coronary Prevention Study (WOSCOPS), the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TexCAPS), and the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) study. [5] [6] [7] 27 The JUPITER protocol was designed and written by the study chair (P.M.R.) and approved by the local institutional review board at each participating center. The trial data were analyzed by the academic cardiologist (B.M.E.), academic study statistician (R.J.G.), and academic programmer (J.M.). The trial was sponsored by AstraZeneca. The trial sponsor monitored the study sites but played no role in the conduct of the analyses or in the drafting of this manuscript. The trial is registered with www.ClinicalTrials.gov (NCT00239681).
As detailed previously, 22 JUPITER was stopped early on March 30, 2008, on the basis of a recommendation by the independent Data and Safety Monitoring Board. At that time, the strength of the evidence for efficacy had exceeded the predetermined stopping boundaries.
Results
Baseline characteristics of the JUPITER populations are show in Table 1 . No significant differences in baseline characteristics were observed between the rosuvastatin and placebo groups.
At the time of study termination (median follow-up, 1.9 years; maximal follow-up, 5 years), 33 strokes had occurred in the rosuvastatin group compared with 64 strokes in the placebo group (Table 2 ). The incidence rates of stroke were 0.18 and 0.34 per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (HR for rosuvastatin, 0.52; 95% CI, 0.34 to 0.79; Pϭ0.002; Table 2 and Figure 1 ). A similar benefit of rosuvastatin was observed for nonfatal strokes, which made up 88 of the 97 strokes observed (HR, 0.52; 95% CI, 0.33 to 0.80; Pϭ0.003). Most strokes were categorized as ischemic, with incidence rates of 0.12 and 0.25 per 100 person-years in the rosuvastatin and placebo groups, respectively (HR, 0.49; 95% CI, 0.30 to 0.81; Pϭ0.004; Table 2 and Figure 1 ).
The rates of hemorrhagic stroke were 0.03 and 0.05 per 100 person-years in the rosuvastatin and placebo groups, respectively. The risk of hemorrhagic stroke was similar in both groups, with an HR of 0.67 (95% CI, 0.24 to 1.88; Pϭ0.44) in the rosuvastatin group compared with the placebo group. TIAs were observed with similar frequency in the 2 treatment groups (HR, 0.93; 95% CI, 0.56 to 1.56; Pϭ0.79).
The projected number needed to treat for 5 years to prevent 1 stroke was 123. When stroke was excluded from the primary cardiovascular end point of myocardial infarction, stroke, unstable angina, revascularization, and cardiovascular death, the number needed to treat to prevent 1 event was projected to be 31 at 5 years. When stroke was included, as it was in the primary end point of the JUPITER trial, the number needed to treat at 5 years was 25, a 19% decrease.
There was no evidence of heterogeneity in any subgroup evaluated (PՆ0.09 for each interaction; Figure 2 ). Rosuvastatin offered a similar benefit across sex and ethnicity groups and to those with and without traditional risk factors for stroke, including subjects who were older (Ͼ70 years of age), were smokers, had hypertension, reported a family history of premature stroke, or had a Framingham stroke risk score Ͼ10%. The benefits of rosuvastatin were also observed in the subgroups that would otherwise be considered at low risk, including those with a body mass index Ͻ25 kg/m 2 , without the metabolic syndrome, with a Framingham stroke or coronary heart disease risk score Յ10, with low levels of LDL-C (Յ100 mg/dL), with normal levels of HDL-C (Ն40 mg/dL among men, Ն50 mg/dL among women), and with normal triglyceride levels (Ͻ150 mg/dL). Likewise, the effects of rosuvastatin were similarly beneficial among those with a baseline hsCRP level Ն5.0 mg/L and those with baseline hsCRP levels Ͻ5.0 mg/L (P for interactionϭ0.35).
We also evaluated whether the magnitude in reduction of LDL-C or hsCRP was directly related to the magnitude of clinical benefit observed, as was observed for the primary end point of JUPITER. 26 As reported previously, after 12 months of therapy, rosuvastatin reduced the median LDL-C by 50% (55 versus 110 mg/dL) and the median hsCRP by 37% (2.2 versus 3.5 mg/L) compared with placebo. 22 However, achieved LDL-C and hsCRP levels were only weakly correlated (rϭ0.10), as were the percentage reduction in LDL-C and percentage reduction in hsCRP (rϭ0.15). 26 As shown in Table 3 , in a subcohort of 15 548 individuals with baseline and 1-year follow-up blood samples available for analysis, the greatest reduction in stroke risk with rosuvastatin was observed among those who reached an LDL-C goal of Ͻ70 mg/dL. In a similar manner, the greatest reduction in stroke risk with rosuvastatin was observed among those who reached an hsCRP goal of Ͻ2 mg/L. For both LDLC and hsCRP, these effects persisted after adjustment for a wide range of baseline characteristics.
Although none of the 3 prior primary prevention trials of statin therapy individually demonstrated a statistically significant reduction in stroke, all suggested trends toward net benefit. The characteristics of JUPITER, WOSCOPS, AFCAPS/Tex-CAPS, and MEGA are presented in Table 4 . In an updated random-effects meta-analysis including the JUPITER data described here, a net 25% reduction in stroke risk was observed (relative risk [RR], 0.75; 95% CI, 0.57 to 0.99; Pϭ0.03; Figure 3 ). Aside from a small increase in physician-reported diabetes in the rosuvastatin group (270 versus 216; Pϭ0.01), adverse events were similar in the 2 arms of the trial and are the same as those reported previously. 22 
Discussion
In this randomized trial of apparently healthy men and women with elevated levels of hsCRP but low levels of LDL-C, rosuvastatin reduced the incidence of stroke by 48%. This reduction in stroke risk was consistent across all subgroups evaluated, including those customarily considered to be at low risk, such as women, nonsmokers, those with Framingham coronary heart disease scores or stroke scores Յ10%, and those without hypertension at baseline. No effect on hemorrhagic stroke was observed.
Although no significant effects of statin therapy on stroke were observed in the WOSCOPS, MEGA, or AFCAPS/ TexCAPS primary prevention trials, all suggested a trend toward net benefit. In fact, we observe a nonsignificant 14% reduction in stroke risk with statin therapy (RR, 0.86; 95% CI, 0.66 to 1.10; Pϭ0.23) in a random-effects meta-analysis using data from these 3 trials. When that analysis is updated with data from JUPITER, statin therapy in primary prevention is associated with a net 25% reduction in stroke risk (RR, 0.75; 95% CI, 0.57 to 0.97; Pϭ0.03; Figure 3 ) without any evidence of heterogeneity (Pϭ0.24). Thus, although there is †A family history of premature stroke was defined as diagnosis of the disease in a male parent before 55 years of age or in a female parent before 65 years of age.
‡The metabolic syndrome was defined according to consensus criteria of the American Heart Association and the National Heart, Lung and Blood Institute. 34 §To convert values for LDL-C, HDL-C, and total cholesterol to mmol/L, multiply by 0.02586. no evidence of heterogeneity between trials, the results of JUPITER must be included in the meta-analysis to observe a statistically significant reduction in stroke in a primary prevention population.
Given the net benefit of statin therapy observed in our updated meta-analysis, it is possible that any apparent differences between JUPITER and each of the prior trials may simply reflect the play of chance. However, the larger relative and absolute benefits observed within JUPITER could also reflect the fact that, unlike the prior trials that used elevated lipid levels as entry criteria, JUPITER targeted those with elevated levels of hsCRP, which in several populations is more closely associated with incident stroke than elevated LDL-C. 3, 4, 15, 17, 28 JUPITER also used a more potent statin regimen than was used in any of the prior trials. Thus, actively treated participants had greater LDL-C and hsCRP reductions. In JUPITER, we observed a 47-mg/dL reduction in LDL-C and a 48% reduction in stroke risk, or a 39% relative reduction in the risk of stroke per 1-mmol/L reduction in LDL-C. In contrast, assignment to pravastatin in WOSCOPS and MEGA was associated with a 41-and 29-mg/dL reduction in LDL-C, respectively, and no significant reduction in the risk of stroke. Statins are generally thought to be equally efficacious per unit of LDL-C reduction, and the Cholesterol Treatment Trialists' Collaborative meta-analysis of previous primary and secondary prevention statin trials reported a 17% relative reduction in the risk of stroke for each 1-mmol/L (38.7-mg/dL) reduction in LDL-C. 29 The summary RR from our meta-analysis of primary prevention trials is consistent with the result from the Cholesterol Treatment Trialists' Collaborative, and the results of JUPI-TER, considered individually, are consistent with the results of trials of different statins conducted in higher-risk populations, including those with diabetes, hypertension, and preexisting coronary or vascular disease. [11] [12] [13] 30 In our data, the lowest risk of stroke was observed among those assigned to rosuvastatin who achieved low levels of LDL-C or hsCRP. This observation is consistent with the association between the risk of the primary end point in JUPITER and achieved LDL-C and hsCRP levels and with prior observations in patients with acute coronary syndromes. 24 -26 Although none of the subjects enrolled in JUPITER would qualify for lipid-lowering therapy by Adult Treatment Panel III criteria, 31 these data suggest that achieving a goal LDL-C of Ͻ70 mg/dL or a goal hsCRP of Ͻ2 mg/L is associated with the greatest reduction in stroke rates in the JUPITER primary prevention population.
In contrast to the results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, we observed no significant difference in the rates of hemorrhagic stroke between the 2 treatment arms in JUPITER. 14 The results from JUPITER are consistent with results from Figure 2 . Effects of rosuvastatin on the prespecified secondary end point of stroke according to baseline characteristics. Stroke is defined as fatal and nonfatal stroke, including ischemic, hemorrhagic, and unclassified types of stroke. The relative HRs for rosuvastatin vs placebo are shown. The size of each black square is proportional to the number of subjects in that category; the horizontal lines represent 95% CIs; and the dashed line represents the overall risk reduction for the entire trial cohort. P values for interaction are also presented. BMI indicates body mass index; Hx, history.
Cholesterol and Recurrent Events (CARE), Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID), and Heart Protection Study (HPS) and with prior work suggesting that achieved LDL-C is not related to hemorrhagic stroke risk. 11, 30, 32 The rates of TIA were similar in both arms of the trial. Although this finding differs from some prior reports such as those from SPARCL and HPS, our observations are consistent with those observed in other trials such as MEGA, CARE, and the Study of Pravastatin in the Elderly at Risk (PROSPER). 7, 11, 14, 30, 33 The lack of association between statin therapy and rates of TIA in JUPITER may be due to a misclassification of nonvascular neurological events as TIAs. However, the criteria used to distinguish a TIA from other neurological syndromes (including stroke) were the same in our study as they were in trials that have and have not shown a reduction in rates of TIA with statin therapy, making a systematic difference between JUPITER and the other trials unlikely.
The main strengths of our study include the large number of participants enrolled; the prospective, randomized, doubleblind treatment assignment; and the prespecification of stroke as an end point. However, the trial was stopped early for evidence of benefit, so the long-term risks and benefits of high-dose statin use in this healthy population should be considered. Furthermore, the number of strokes in our analysis somewhat limits our ability to examine subgroups closely. This issue is particularly important in interpretations of the changes in stroke risk associated with achieved levels of LDL-C and hsCRP.
Conclusions
In this healthy population with normal cholesterol levels but elevated levels of hsCRP, random allocation to rosuvastatin was associated with a 48% reduction in the risk of incident stroke. The benefits of rosuvastatin were observed across all subgroups, including those at low risk for stroke, and we observed no increase in the risk of hemorrhagic stroke with active therapy. 34
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